Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial

  • Additional readouts from Valneva SE's VALN pivotal VLA2001-301 "Cov-Compare" trial of COVID-19 vaccine VLA2001 showed persistent and first positive heterologous booster results following AstraZeneca Plc's AZN COVID-19 primary vaccination.
  • After two months, neutralizing antibody titers induced by VLA2001 was non-inferior to AstraZeneca's COVID shot (ChAdOx1-S).
  • GMT was 444.0, and ChAdOx1-S GMT was 411.8. 
  • Related: Valneva Cuts FY22 COVID-19 Vaccine Sales Outlook, Needs Funding To Invest In Next-Gen COVID-19 Shot.
  • Seroconversion rates remained constant (above 92% in both treatment groups). 
  • Additionally, approximately six months after primary vaccination showed that VLA2001 induced broad antigen-specific IFN-gamma-producing T-cells reactive against the S-protein and the N- and M-proteins.
  • The safety profile of VLA2001 continues to be favorable, and the vaccine was well tolerated.
  • The occurrence of COVID-19 cases was similar between the VLA2001 and ChAdOx1-S groups.
  • Neutralizing antibody titers following a VLA2001 booster dose administered approximately eight months after primary vaccination were between 3-fold (heterologous) to 28-fold (homologous) higher than pre-boost levels, in line with previous VLA2001 Phase 1/2 homologous booster results. 
  • Price Action: VALN shares closed at $18.03 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!